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Diuretic Efficacy of High Dose Furosemide in Severe Heart Failure: 
Bolus Injection Versus Continuous Infusion
TOM P. J. DORMANS, MD, JOSEPH J. M. v a n  MEYEL, MD, PhD,* 
PAUL G. G. GERLAG, MD, PhD ,! YUEN TAN, FRANS G. M. RUSSEL, PhD, 
PAUL SMITS, MD, PhD
Nijmegen, Amsterdam and Veldhoven} The Netherlands
Objectives. The efficacy of high dose furoseraide as a continuous 
infusion was compared with a bolus injection of equal dose in 
patients with severe heart failure.
Background, The delivery rate of furosemide into the nephron 
has been proved to be a determinant of diuretic efficacy in healthy 
volunteers.
Methods. In a randomized crossover study we compared the 
efficacy of a continuous infusion of high dose furosemide (mean 
daily dosage 690 mg, range 250 to 2,000) versus a single bolus 
injection of an equal dose in 20 patients with severe heart failure. 
The patients received an equal dosage, either as a single intrave­
nous bolus injection or as an 8-h continuous infusion preceded by 
a loading dose (20% of total dosage).
Results. Mean (±SEM) daily urinary volume (infusion 2,860 ±  
240 ml, bolus 2,260 ± 150 mi, p =  0.0005) and sodium excretion
(infusion 210 ±  40 mmol, bolus 150 ±  20 mmol, p = 0.0045) were 
significantly higher after treatment with continuous infusion than 
with bolus injection, despite significantly lower urinary furo­
semide excretion (infusion 310 ± 60 mg every 24 h, bolus 330 ± 
60 mg every 24 h, p = 0.0195). The maximal plasma furosemide 
concentration was significantly higher after bolus injection than 
during continuous infusion (infusion 24 ± 5 /xg/ml, bolus 95 ± 20 
ftg/ml, p < 0.0001). Short-term, completely reversible hearing loss 
was reported only after bolus injection in 5 patients.
Conclusions. We conclude that in patients with severe heart 
failure, high dose furosemide administered as a continuous 
infusion is more efficacious than bolus injection and causes less 
ototoxic side effects.
(J Am Coll Cardiol 1996;28:376- 82)
Loop diuretic drugs are commonly required in the manage­
ment of heart failure. In most patients, orally administered 
conventional dosages of furosemide mobilize edema and main­
tain adequate hydration. However, with progression of the 
disease state, diuretic resistance—a potentially life-threatening 
phenomenon—frequently occurs, resulting in fluid and sodium 
retention. To overcome this complication the oral dosage of 
the loop diuretic drug is often increased. There are two reasons 
for this strategy: 1) In the course of heart failure, impairment 
of renal function often occurs (1). In renal insufficiency, higher 
dosages of furosemide are necessary to create effective con­
centrations in the intraluminal site of the ascending limb of 
Henle’s loop, the site of action of loop diuretic drugs. 2) In 
patients with heart failure, higher concentrations of furo­
semide in the renal tubule are required to induce an adequate
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natriuretic response; in other words, in these patients the 
dose-response curve is shifted to the right and downward (2).
In addition to the absolute amount of drug carried to the 
site of action, the time course of delivery to the site of action 
appears to be an important determinant of overall diuretic 
response (3,4). This means that, theoretically, diuretic treat­
ment can be optimized by the administration of furosemide as 
a continuous intravenous infusion. This mode of administra­
tion provides a constant delivery rate of furosemide to the 
renal tubule, Furthermore, sodium retention during the drug- 
free intervals may be avoided and the risk of ototoxic side 
effects reduced (5,6).
Only two controlled studies have compared the efficacy of a 
continuous intravenous infusion of a loop diuretic drug with 
intravenous bolus administration in patients with heart failure 
(7,8), with conflicting results with respect to the supposed 
superior efficacy of continuous infusion. However, on the basis 
of the previous arguments and the results of studies in healthy 
volunteers and patients with renal insufficiency, optimizing 
furosemide delivery to the renal tubule may have a beneficial 
effect. Consequently, we hypothesized that high dose furo­
semide administered as a continuous intravenous infusion 
would be more efficacious and less toxic than an intravenous 
bolus of an equal dosage of furosemide in patients with severe 
chronic heart failure.
pit
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Table 1, Clinical Characteristics of 20 Study Patients
Pt No* Age (yr)/Gender
Weight
(kg)
Weight
Change
(kg)
Creatinine
Clearance
(ml/min)
Hydration
Status Diagnosis Dose (mg)
Additional
Medication
1 74/M 70.1 0.0 46 Comp CAD 500 A t C
2 74/M 106.9 - 1.6 92 Comp CP 1,000 Al, P, T, Th
3 73/F 78.5 -0.3 70 Comp CAD 250 A, T, N, P
4 83/F 83.9 - 1.2 59 Comp CAD 250 A, C, D, I, T
5 56/M 90.4 + 1.2 87 Comp CM 500 A, Am, C, P
6 76/M 57.2 -1.3 27 Comp CAD 500 Al, I, Ibf Th
7 73/F 83.0 - 1.6 16 Comp CAD 500 A, Am, I, P, T
8 72/M 48.3 -0.5 15 Comp CAD 1,500 A, Am, I
9 51/F 36.6 -0.5 15 Comp CAD 2,000 A, I, lb, Ac
10 82/M 61.2 -2.7 43 Decomp CAD 500 D, T, Tr
11 71/M 81.9 - 6.6 50 Decomp CM 250 Ac, Am, C, D, I, Pr, T, Th
12 85/M 72.4 - 12.8 32 Decomp CAD 250 C, D, Ac
13 86/F 56.3 -3.8 34 Decomp CAD 500 AI,C
14 89/F 63.9 -0.9 32 Decomp CAD 1,000 D, lb
15 69/F 76.5 - 1.0 52 Decomp CP 250 A, C, H, Th
16 66/M 78.0 -0.5 50 Decomp CAD 500 Am, C, P, T
17 66/M 71.0 -1.3 57 Decomp CM 2,000 A, All, C, D, Th
ÏS 57/M 79.7 -2.7 46 Decomp VD 250 C, D, P
19 69/M 63.6 - 1.8 24 Decomp CAD 1,000 CST
20 51/M 98.2 -4.4 45 Decomp CAD 250 Al, D
Mean 71 72.9 -2.3 45 690
±SEM 2.5 3.7 -0.7 ' 4.8 120
A =  amiloride; Ac = acenocoumarol; A1 = AJdactone; All = allopurmol; Am = amiodarone; C = captopril; CAD = coronary artciy disease; CM = cardiomyopathy; 
Comp =  compensated heart failure; CP = cor pumonale; D = digoxin; Decomp = decompensated heart failure; F = female; H = hydrochlorothiazide; I = isosorbide 
dinitrate; lb = ibopamine; M = male; N = nifedipine; P = potassium; Pr = prednisone; Pt = patient; T = tolbutamide; Th = theophylline; Tr = triamterene; VD = valvular 
disease.
Methods
Subjects. After approval by the local ethics committee, we 
included 20 patients (7 women, 13 men) with severe heart 
failure of differing etiologies (New York Heart Association 
functional class III or IV) and long-term use of orally admin­
istered high dose furosemide (at least 250 mg), Each patient 
provided written informed consent before the start of the 
study. No patient was taking nonsteroidal anti-inflammatory 
drugs or probenecid. Patients with a cardiomyopathy due to 
alcoholism were excluded.
At the time of the study, 9 patients were in a clinically 
compensated state without edema, and 11 patients had decom­
pensated heart failure with an estimated edematous mass of at 
least 5 kg. Mean (±SEM) body weight at the start of the study 
was 72.9 ±3.7 kg. Mean pretreatment endogenous creatinine 
clearance rate was 45 ± 4 ml/min. The clinical characteristics 
of the study patients are shown in Table 1.
Study design. The study was a randomized crossover study. 
All patients were placed on a standard diet of 80 mmol of 
sodium and 100 mmol of potassium and a fluid intake of 1,500 
ml. Extra potassium was administered for hypokalemia (<3.5 
mmol/liter). During the study, patients did not drink coffee, tea 
or alcohol. The daily furosemide dosage was left unchanged 
throughout the study. All other medication was continued as 
previously prescribed. Patients underwent physical examina­
tion with emphasis on hydration status. Standing and supine
blood pressures and weight were determined daily. An indwell­
ing urinary catheter was inserted when patients could not void 
on request. The patients remained in the hospital for the 
duration of the study.
During days 1 and 2 of the study, the patients received a 
single dose of orally administered furosemide (Lasix, Hoechst). 
At that time, blood samples were obtained for baseline measure­
ment of serum electrolytes, blood cell counts, serum albumin, 
plasma epinephrine and norepinephrine, plasma renin and 
plasma aldosterone. Urine samples were collected over 24 h 
for measurement of volume and concentrations of creatinine, 
sodium, potassium, chloride and furosemide.
On day 3, patients were randomized to receive furosemide 
either as an intravenous bolus injection (injected within 5 min) 
or as a continuous intravenous infusion. The continuous 
intravenous infusion started with a loading dose consisting of 
20% of the total dose and administered within 5 min as a bolus 
injection, followed by an 8-h continuous intravenous infusion 
at an infusion rate of 10% of the total dose per hour (model 
STC-521 infusion pump, Terumo Corp., Tokyo, Japan). Either 
of the administration modes was started at 8 a m , after initial 
bladder emptying. Blood samples were taken from the antecu- 
bital vein in the arm contralateral to the drug infusion at 0,15, 
30, 45, 60, 90, 120,150,180, 240, 360, 480 and 1,440 min after
the start of the intravenous furosemide administration for 
determination of plasma furosemide concentrations. Urine
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Table 2. Mean Values (±SEM) of Biochemical Variables in 20 Patients With Severe Heart 
Failure Before and After Intravenous Treatment with High Dose Furosemide (daily dosage 
690 ± 560 mg)
Day 2
Before 
Infusion 
(t = 0 h)
Days 3-5
After Before 
Infusion Bolus 
(t -  24 h) (t = 0 h)
After 
Bolus 
(t -  24 h) Day 6
Serum sodium (mmol/liter) 137 ± 1 137 ± 1 138 ± 1 138 ± 1
Serum potassium (mmol/liter) 4.2 ±0.1 4,3 ± 0.2 4.1 ± 0.1 4.3 ± 0.1
Serum chloride (mmol/liter) 95 ±1 94 ± 2 95 ± 1 94 ± 2
Serum creatinine (jumol/liter) 132 ± 8 139 ± 9* 134 ± 8 139 ± 8f
Serum urea (mmol/liter) 18 ± 2 19 ± 2 19 ± 2 19 ± 2
Serum albumin (g/liter) 36 ±1 37 ± 1 36 ± 1 36 ± 1
Aldosterone (nmol/liter) 1.5 ±0.2 1.8 ± 0.5
Renin (ng/liter) 222 ± 62 336 ± 109
Epinephrine (nmol/liter) 0.4 ± 0.1 0.3 ± 0.1
Norepinephrine (nmol/liter) 3.5 ± 0.5 2.8 ± 0.4
*p < 0.01, fp <  0,05 versus before treatment {Student t test for paired data), t = time.
was collected at 30, 60, 120, 180, 240, 360, 420, 480 and 
1,440 min after the start of furosemide administration for 
measurements of volume, sodium, potassium, chloride, creat­
inine and furosemide. Intravenous furosemide preparations as 
well as all urine samples were protected against light to prevent 
photochemical degradation of furosemide.
Urine losses were not replaced isovolumetrically. Day 4 was 
used as a washout period: Patients received oral furosemide 
medication, and blood and urine sampling was identical to the 
first 2 days.
On day 5 the crossover mode of intravenous administration 
was performed as described previously. On the final day (day 
6), urine was collected, and blood samples (including renin, 
aldosterone and catecholamines) were taken for comparison 
with baseline measurements.
Analytic methods. Sodium and potassium concentrations 
were measured by flame photometry, chloride concentrations 
by a semiautomatic colometric titration method and creatinine 
concentrations according to the Jaffe reaction in an autoana­
lyzer. Plasma and urine concentrations of furosemide were 
measured by a rapid and sensitive high performance liquid 
chromatographic assay, as described previously (9). Plasma 
aldosterone was determined by radioimmunoassay (10). 
Plasma renin was measured by means of an immunoradiomet- 
ric sandwich technique with the use of two monoclonal anti­
bodies and without enzymatic step (ERIA Diagnostics Pasteur, 
Marnes La Coquette, France) (11). Blood samples for mea­
surement of plasma catecholamines were collected in pre­
chilled tubes on melting ice containing glutathione (0.2 mol/ 
liter) and ethylenediaminetetraacetic acid (0.25 mol/liter). The 
tubes were centrifuged at 4°C, and plasma was stored at 
-80°C; analyses of plasma samples occurred within 2 months 
of collection. Plasma samples were analyzed for concentrations 
of catecholamines by high performance liquid chromatography 
with fluorometric detection after precolumn derivatization 
with the selective detection agent 1,2-diphenylethylenediamine.
The laboratory procedure is a modification of a previously 
described method (12).
Data analysis. The plasma concentration data obtained 
after bolus injection were fitted to an open two-compartment 
model by use of the PCNonlin computer program (13). The 
area under the curve (AUC) was calculated by direct integra­
tion, and the half-life of furosemide was obtained from the 
terminal elimination rate constant. The AUC below the 
plasma concentration-time curve during continuous infusion 
was calculated by means of the trapezoid rule and extrapola­
tion to infinity using the terminal elimination rate constant of 
the curve after bolus injection. Systemic clearance was deter­
mined by dividing the furosemide dose by the AUC. Renal 
clearance was calculated as the amount of excreted drug 
during 24 h divided by the AUC. Nonrenal clearance was 
defined as the systemic clearance minus the renal clearance. 
Overall efficiency was calculated by dividing the excreted 
amount of sodium (mmol/24 h) by the excreted amount of 
furosemide (mg/24 h).
Statistical analysis. Statistical analyses of unpaired and 
paired data were made using the Student t test and the Student 
t test for paired data, respectively. A p value <0.05 was 
considered significant. Data are expressed as mean value ±
SEM.
Results
Biochemical measurements. Mean values of the biochem­
ical measurements, including catecholamines, renin and aldo­
sterone, did not change significantly during the study, with the 
exception of serum creatinine, which showed a significant 
increase after both treatment modes (Table 2). As shown in 
Table 1, the endogenous creatinine clearance was reduced in 
the majority of the patients. According to the natriuresis, 13 
patients were not resistant to oral therapy (Table 3). However, 
six of these patients had a clearly negative sodium balance
JACC Vol. 28, No. 2
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Table 3, Urinary Volume, Electrolyte and Furosemide Excretion (mean ± SEM) 8  and 24 h After Administration of Furosemide as Oral 
Dosage (day 2), Intravenous Bolus Injection or Continuous Infusion in Patients With Heart Failure
Oral, 0-26 h
Bolus Infusion
Bolus Versus Infusion 
(p value)
0-8  h 0-24 h 0-8  h 0-24 h 0-8  h 0-24 h
U (ml) 2,200 ± 160 1,350 ± 90 2,260 ± 150 1,700 ± 120 2,860 + 240 0.0002 0.0005
UNa (mmol) 130 ± 30 110 ± 10 150 ± 20 140 ± 20 210 ± 40 0.0010 0.0045
UK (mmol) 70 ± 6 30 ± 5 70 ± 5 40 ± 4 80 ± 5 0.0006 <  0.0001
Ua  (mmol) 130 ± 20 120 ± 10 150 ± 20 150 ± 20 220 ±  35 0,0006 0.0018
^furusernide (^S) 140 ± 30 290 ± 50 330 ± 60 220 ± 40 310 ± 60 < 0.0001 0.0195
Recovery (%) 21 ± 2 44 ± 2 50 ± 2 33 ± 2 44 ± 2 <  0.0001 0,0195
Efficiency (mmol/mg) 2.9 ± 1.5 0.7 ± 0,2 0.9 ± 0.3 1,1 ± 0.3 1,3 ± 0,4 0.0005 0.0019
Statistical analyses were made using the Student t test for paired data. Ua  -  urinary chloride excretion; Ufuroscmidc = urinary furosemide excretion; UK = urinary 
potassium excretion; UNa -  urinary sodium excretion; Uv = urinary volume.
I
(>20  mmol/24 h) and did not lose weight during this phase of 
the study, suggesting poor compliance with the dietary restric­
tions.
2 h, whereas during continuous infusion, the urinary excretion 
rate was constant.
Pharmacodynamic measurements. Although a smaller
A n influence of cotreatment with angiotensin-converting amount of furosemide was excreted in the urine during both 8 
enzyme on the diuretic response could not be observed. The and 24 h with the use of continuous infusion, the urinary 
renin levels between captopril-treated and non-captopril- volume and natriuresis during both 8 and 24 h were signifi-
treated patients did not differ significantly.
Pharmacokinetic measurements. Apart from the maximal 
plasma furosemide concentration, which was significantly 
higher after intravenous bolus injection, the pharmacokinetic 
measurements were similar in the two treatment modes (Table 
4). The plasma furosemide concentration-time profiles of the 
two dose regimens of one representative patient are shown in 
Figure 1. The furosemide plasma concentrations were in the 
supposed ototoxic range (>100  /xg/ml) in seven patients im­
mediately after bolus injection and in one patient during 
continuous infusion. During continuous infusion, the plasma 
furosemide concentration remained at steady state throughout 
the infusion period, with a significantly lower maximal plasma
concentration (bolus 95 ± 20 jug/ml, infusion 24 ± 5 jug/ml, 
p <  0.0001). However, the plasma furosemide concentration 
was determined first at 15 min, after the start of the adminis­
tration, This implies that immediately after injection of the 
bolus, the plasma furosemide concentration was even higher. 
The urinaiy furosemide excretion rate followed a similar 
pattern for both methods of administration (Fig. 1). After 
bolus injection, most of the furosemide was excreted within
Table 4. Pharmacokinetic Variables (mean ± SEM) of Furosemide 
A fter Administration as Bolus or Continuous Infusion in 20 Patients 
With Heart Failure
Bolus Infusion
AUC (g/ml per min) 14.2 ± 4.0 13.1 ± 4.1
Systemic clearance (ml/min) 64 ± 8 67 ± 6
Renal clearance (ml/min) 30 ±3 31 ±3
Non renal clearance (ml/min) 34 ±4 36 ±4
Half-life (min) 139 ±7
Furosemide excretion (mg/24 h) 330 ± 60* 310 ± 60
*p < 0.05, Student t test for paired data. AUC = area under the curve.
cantly larger (Table 3). The differences in natriuretic response 
between the two intravenous modes of administration and the
Figure 1. Furosemide plasma concentration (top) and urinary furo­
semide excretion rate (bottom) for a representative study patient 
(Patient 1) after 500 mg of furosemide as a bolus injection or 
continuous infusion (50 mg/h during 8  h preceded by a loading dose of 
1 0 0  mg),
1ÛO r Plasma furosemide concentration (mcg/ml)
75
50'
25
Infusion
Q Bo lus
20OO rFurosemide excretion rate (mcg/min)
1500 -
1000  -
500 -
o
o 120 240 360  480
Tim e (min)
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Figure 2 . Cumulative urinary sodium excretion (mean ± SEM) 24 h 
after bolus injection (open squares) and continuous infusion (solid 
squares) of high dose furosemide.
interindividual variability of these responses are shown in 
Figures 2 and 3.
Separate analysis of data of patients with compensated (n = 
9) and decompensated (n = 11) heart failure revealed similar 
results for these subgroups, except for the urinary furosemide 
excretion. In the two dose regimens there appeared to be a 
significantly lower excretion only in patients with compensated 
heart failure after continuous infusion. The sequence of drug 
administration did not influence the natriuretic response in 
either of the two intravenous administration methods.
Compared with oral therapy (day 2), bolus injection did not 
differ significantly with respect to volume and electrolyte 
excretion. However, urinary recovery of furosemide was signif­
icantly lower (oral 21 ±  2%, bolus 50 ± 2%, p <  0.0001), and 
thus efficiency was higher. When continuous infusion was 
compared with oral therapy, volume and electrolyte excretion 
were significantly higher after continuous infusion, whereas 
urinary furosemide recovery was significantly lower after oral 
administration (oral 21 ±  2%, infusion 44 ± 2%, p <  0.0001).
Figure 3. Individual values for urinary sodium excretion 24 h after 
continuous infusion and bolus injection of high dose furosemide in 2 0  
patients with severe heart failure.
Urinary sodium excre tion  (mmol/24 hrsj
8 0 0
7 0 0
6 0 0
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3 0 0
200
100
o
T
I
A dose-response curve was created for each patient. How­
ever, sigmoid-shaped curves, as seen in healthy subjects, were 
not observed (data not shown). Moreover, a high interindi­
vidual variability was observed.
To gain insight into the potential development of acute 
diuretic tolerance during continuous infusion of furosemide, 
we compared the efficiency (mmol excreted sodium/mg ex­
creted furosemide) during two time intervals—30 to 60 min 
and 420 to 480 min. The amount of drug excreted per hour 
during each interval did not differ significantly, nor did the 
amount of sodium. Hence, the efficiency was equal in both 
periods, indicating that acute diuretic tolerance did not occur 
during continuous infusion. Because of the design of the study 
(a single bolus instead of multiple), we could not determine 
whether acute drug tolerance was present after bolus injection.
Side effects. Although five patients reported hearing loss or 
tinnitus, or both, shortly after bolus injection, these effects 
appeared to be transient in all five and disappeared within 
15 min. No other side effects were observed or reported during 
this study.
infusion bolus
Discussion
General conclusions. Our results clearly show that in pa­
tients with severe heart failure, continuous infusion of high 
dose furosemide causes excretion of a higher volume of urine 
and electrolytes than an equal dose administered as an intra­
venous bolus, and the maximal plasma furosemide concentra­
tion is significantly lower. A crossover design in combination 
with a washout period was used to balance out any possible 
time or sequence trends. Moreover, the pharmacokinetic data 
obtained supported the outcome of the study.
Comparison with previous studies. Few data are available 
on the usefulness of continuous infusion of furosemide in 
disease, particularly heart failure. In an animal study, Lee et al. 
(14) compared different durations of infusion of an equal 
dosage of furosemide. The diuretic response increased with 
increasing infusion times. In healthy volunteers a controlled 
comparison of bolus injection with continuous infusion of a 
conventional dosage of furosemide showed a larger diuretic 
effect of the latter mode of administration (5). In chronic renal 
insufficiency, continuous infusion of bumetanide was more 
effective and less toxic than intermittent bolus therapy (15), 
Several uncontrolled reports describing small series of patients 
with congestive heart failure demonstrate successful applica­
tion of continuous infusion of loop diuretic drugs (5,16-20). 
To our knowledge only two controlled studies on this subject 
have been performed in adult patients with heart failure (7,8). 
Copeland et a l (8) did not find any significant pharmacody­
namic differences in a comparison of continuous intravenous 
infusion and an equal dose given as two separate bolus 
injections in patients after cardiac surgery. However, that study 
lacked a crossover design, use of a loading dose before the start 
of continuous infusion and adequate study period. Lahav et al 
(7) compared intermittent administration of furosemide with a 
continuous infusion of an equal dose in patients with conges-
tive heart failure. In their study, which lacked pharmacokinetic 
data, continuous infusion was shown to be the preferred 
method of administration. In both studies, conventional dos­
ages of furosemide were used.
In our study the dosage of furosemide was >250 mg/day in 
all patients. The results of the present study cannot be 
generalized to patients receiving furosemide in the conven­
tional dose range. However, in the conventional dose range, a 
continuous infusion is usually not necessary because diuretic 
resistance can be overcome by simply increasing the dosage.
Interpretation of pharmacokinetic and pharmacodynamic 
data. In the present study, we included those patients who 
would benefit most from the presumed advantages of contin­
uous infusion of furosemide, that is, patients with heart failure 
and, often, impaired renal function. High dose furosemide is 
used in these patients because of diuretic resistance to con­
ventional dosages. Thus, they are in need of an optimal 
diuretic regimen without toxic side effects, The higher effi­
ciency of continuous infusion is demonstrated by the observa­
tion that a smaller amount of drug excreted into the urine 
produced a larger natriuretic effect (Table 3). Several mecha­
nisms may elicit this superior response: 1) the time course of 
delivery of furosemide into urine. Because the amount of drug 
excreted into the urine is even smaller after continuous 
infusion, the time course of delivery is consequently an impor­
tant factor influencing the diuretic response* The maximally 
efficient excretion rate of furosemide can be calculated, and 
the slope factor of the dose-response curve appears to be an 
important determinant in this calculation (3,4), In healthy 
volunteers the maximally efficient excretion rate appeared to 
be 115 /xmol/min (4). As in patients with heart failure studied 
by Brater et al. (2), the dose-response curves of the patients in 
the present study were shifted to the right. Moreover, the 
sigmoid shape could not be recognized, making calculation of 
the maximally efficient excretion rate impossible. For this 
reason and because of the larger interindividual variability, an 
optimal infusion rate of furosemide cannot be predicted in 
these patients. However, it is obvious that during continuous 
infusion, the urinary furosemide excretion rate will be closer to 
the maximally efficient excretion rate over a longer period.
2) Another reason for the observed difference in response 
between the two modes of administration could be the devel­
opm ent of a more pronounced acute drug tolerance after bolus 
injection (21). Because of a greater diuresis during the period 
immediately after the injection, the intravascular volume might 
decrease even in a volume-overloaded patient, causing activa­
tion of sodium- and volume-retaining mechanisms. The net 
result may be lower diuretic efficacy despite adequate urinary 
furosemide concentrations. Because we used only one bolus 
injection instead of multiple intermittent injections, the pres­
ence of acute tolerance could not be verified. Acute diuretic 
tolerance during continuous infusion appeared to be absent.
3) After bolus injection, the drug-free interval, during which 
counteracting sodium-retaining mechanisms are active, is 
longer. Although catecholamine levels were increased at the 
start of the study, they were not further increased at the end of
JACC Vo!. 28, No. 2
August 1996:376-82
the study. Activation of the renin-angiotensin-aldosterone axis 
was not observed (Table 2). However, variables were measured 
at the start and end of the study, so a transient activation could 
have been missed.
In chronic heart failure, long-term coadministration of 
angiotensin-converting enzyme inhibitors may enhance 
furosemide-induced natriuresis, possibly owing to a change in 
the set point for renal sodium handling (22). In 9 of 20 patients 
in this study, angiotensin-converting enzyme inhibitors were 
withdrawn in an earlier phase because of further deterioration 
of renal function or symptomatic hypotension. Comparison of 
the patients treated with and without angiotensin-converting 
enzyme inhibitors did not reveal any differences in furosemide- 
induced natriuresis for any of the modes of administration, and 
the mean daily dosage of furosemide did not differ significantly 
between the two groups.
Side effects. An important advantage of the use of contin­
uous infusion is a smaller risk of ototoxicity because high peak 
plasma levels of furosemide are avoided (6). In the present 
study the measured maximal plasma concentration during 
continuous infusion was lower than that after bolus injection in 
all patients. However, even a continuous infusion of high dose 
furosemide may lead to concentrations in the supposed oto­
toxic range in patients with severe renal insufficiency, as 
illustrated by one of the study patients (Patient 9, endogenous 
creatinine clearance 15 ml/min per 1.73 m2, furosemide dosage 
2,000 mg, maximal plasma concentration in the course of 
continuous infusion 119 jug/ml). According to our clinical 
experience, an infusion rate of 160 mg/h seems safe when the 
endogenous creatinine clearance rate is >20 ml/min per 1.73 
m2 (5).
Intravenous versus oral treatment. We observed a higher 
urinary recovery of furosemide after bolus injection than with 
continuous infusion. This difference reached significance only 
in the compensated group of patients. The exact mechanism of 
this discrepancy is not clear and needs further exploration. 
Although the urinary recovery of furosemide after oral therapy 
is much lower (Table 3), owing to lower bioavailability than 
after bolus injection, its efficacy is equal. This means that the 
efficacy is greater after oral therapy than after bolus injection, 
which is probably the result of a better time course of delivery. 
Although efficacy was equal for both oral therapy and contin­
uous infusion, continuous infusion of an equal dose is more 
efficacious than oral administration because of a higher urinary 
excretion rate of furosemide with continuous infusion (Table
3). In patients with congestive heart failure, absorption of 
furosemide after oral therapy is delayed, which results in a 
lower drug concentration at the site of action. An increase in 
oral dosage is less attractive because the exact duration of 
delay is unknown, making the response unpredictable. For this 
reason, patients with manifest decompensated heart failure 
should preferably be treated with intravenous therapy until the 
hydration state is corrected.
Summary. The value of continuous infusion of furosemide 
in patients with severe congestive heart failure can be summa­
rized as follows: A higher efficiency (than with bolus injection)
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and a higher, more predictable urinary excretion rate of drug 
(than after oral therapy) results in an improved diuretic 
response combined with a reduced risk for ototoxicity. Contin­
uous infusion of furosemide should be considered in patients 
with decompensated heart failure whenever the diuretic re­
sponse after oral therapy with high dose furosemide is insuf­
ficient, especially in those patients at risk for furosemide- 
induced toxicity because of impaired renal function.
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